Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-Dose Chemotherapy

This study has been completed.
Information provided by Amgen

Please refer to this study by its ClinicalTrials.gov identifier: NCT00041665

Sponsors and Collaborators

Investigators